Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Catherine Sermet

Showing results (11-20 of 24) with videos related to

Pageof 3
Sort By:
Pharmacoeconomics|June 7, 2015
Disinvestment and Value-Based Purchasing Strategies for Pharmaceuticals: An International ReviewBonny Parkinson, Catherine Sermet, Fiona Clement, et al.
BMC Health Services Research|June 10, 2010
Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payersJakub Adamski, Brian Godman, Gabriella Ofierska-Sujkowska, et al.
Pharmaceuticals (Basel, Switzerland)|October 8, 2016
Use of Generics-A Critical Cost Containment Measure for All Healthcare Professionals in Europe?Brian Godman, William Shrank, Bjorn Wettermark, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|December 16, 2010
Comparing policies to enhance prescribing efficiency in Europe through increasing generic utilization: changes seen and global implicationsBrian Godman, William Shrank, Morten Andersen, et al.
Frontiers in Pharmacology|July 3, 2014
Multiple policies to enhance prescribing efficiency for established medicines in Europe with a particular focus on demand-side measures: findings and future implicationsBrian Godman, Bjorn Wettermark, Menno van Woerkom, et al.
Frontiers in Pharmacology|August 12, 2011
Policies to enhance prescribing efficiency in europe: findings and future implicationsBrian Godman, William Shrank, Morten Andersen, et al.
Frontiers in Pharmacology|October 14, 2016
Payers' Views of the Changes Arising through the Possible Adoption of Adaptive PathwaysMichael Ermisch, Anna Bucsics, Patricia Vella Bonanno, et al.
Frontiers in Pharmacology|June 25, 2014
Dabigatran - a continuing exemplar case history demonstrating the need for comprehensive models to optimize the utilization of new drugsBrian Godman, Rickard E Malmström, Eduardo Diogene, et al.
Frontiers in Pharmacology|August 13, 2016
Introduction and Utilization of High Priced HCV Medicines across Europe; Implications for the FutureWinnie de Bruijn, Cristina Ibáñez, Pia Frisk, et al.
Frontiers in Pharmacology|September 8, 2017
Adaptive Pathways: Possible Next Steps for Payers in Preparation for Their Potential ImplementationPatricia Vella Bonanno, Michael Ermisch, Brian Godman, et al.
Pageof 3

Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
Pharmacoeconomics|June 7, 2015
Disinvestment and Value-Based Purchasing Strategies for Pharmaceuticals: An International ReviewBonny Parkinson, Catherine Sermet, Fiona Clement, et al.
BMC Health Services Research|June 10, 2010
Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payersJakub Adamski, Brian Godman, Gabriella Ofierska-Sujkowska, et al.
Pharmaceuticals (Basel, Switzerland)|October 8, 2016
Use of Generics-A Critical Cost Containment Measure for All Healthcare Professionals in Europe?Brian Godman, William Shrank, Bjorn Wettermark, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|December 16, 2010
Comparing policies to enhance prescribing efficiency in Europe through increasing generic utilization: changes seen and global implicationsBrian Godman, William Shrank, Morten Andersen, et al.
Frontiers in Pharmacology|July 3, 2014
Multiple policies to enhance prescribing efficiency for established medicines in Europe with a particular focus on demand-side measures: findings and future implicationsBrian Godman, Bjorn Wettermark, Menno van Woerkom, et al.
Frontiers in Pharmacology|August 12, 2011
Policies to enhance prescribing efficiency in europe: findings and future implicationsBrian Godman, William Shrank, Morten Andersen, et al.
Frontiers in Pharmacology|October 14, 2016
Payers' Views of the Changes Arising through the Possible Adoption of Adaptive PathwaysMichael Ermisch, Anna Bucsics, Patricia Vella Bonanno, et al.
Frontiers in Pharmacology|June 25, 2014
Dabigatran - a continuing exemplar case history demonstrating the need for comprehensive models to optimize the utilization of new drugsBrian Godman, Rickard E Malmström, Eduardo Diogene, et al.
Frontiers in Pharmacology|August 13, 2016
Introduction and Utilization of High Priced HCV Medicines across Europe; Implications for the FutureWinnie de Bruijn, Cristina Ibáñez, Pia Frisk, et al.
Frontiers in Pharmacology|September 8, 2017
Adaptive Pathways: Possible Next Steps for Payers in Preparation for Their Potential ImplementationPatricia Vella Bonanno, Michael Ermisch, Brian Godman, et al.
Pageof 3